The following is a listing of myeloma treatments associated with this tag.
View all treatments in development for myeloma patients around the US.
Iopofosine I-131 (CLR 131)
Iopofosine I 131 (CLR 131) is a phospholipid drug conjugate (PDC) that selectively delivers radiation (a cytotoxic radioisotope called iodine-131) directly to malignant cancer cells. The US Food and Drug Administration (FDA) has granted Cellectar an orphan drug designation for Iopofosine I 131 (CLR 131).
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.
Iopofosine I-131 (CLR 131)
Iopofosine I 131 (CLR 131) is a phospholipid drug conjugate (PDC) that selectively delivers radiation (a cytotoxic radioisotope called iodine-131) directly to malignant cancer cells. The US Food and Drug Administration (FDA) has granted Cellectar an orphan drug designation for Iopofosine I 131 (CLR 131).
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.
Iopofosine I-131 (CLR 131)
Iopofosine I 131 (CLR 131) is a phospholipid drug conjugate (PDC) that selectively delivers radiation (a cytotoxic radioisotope called iodine-131) directly to malignant cancer cells. The US Food and Drug Administration (FDA) has granted Cellectar an orphan drug designation for Iopofosine I 131 (CLR 131).
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of myeloma clinical trials associated with this tag.
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.